company background image
4743

Oneness Biotech TPEX:4743 Stock Report

Last Price

NT$185.00

Market Cap

NT$71.5b

7D

-2.6%

1Y

-5.6%

Updated

16 May, 2022

Data

Company Financials
4743 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4743 Stock Overview

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan.

Oneness Biotech Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Oneness Biotech
Historical stock prices
Current Share PriceNT$185.00
52 Week HighNT$338.00
52 Week LowNT$165.00
Beta1.41
1 Month Change-6.80%
3 Month Change-23.71%
1 Year Change-5.61%
3 Year Change589.01%
5 Year Change591.59%
Change since IPO1,121.46%

Recent News & Updates

Shareholder Returns

4743TW PharmaceuticalsTW Market
7D-2.6%-4.6%-3.4%
1Y-5.6%3.0%0.7%

Return vs Industry: 4743 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 4743 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 4743's price volatile compared to industry and market?
4743 volatility
4743 Average Weekly Movement6.7%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4743 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4743's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2008n/aChih-Hui Chenghttps://www.onenessbio.com.tw

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.

Oneness Biotech Fundamentals Summary

How do Oneness Biotech's earnings and revenue compare to its market cap?
4743 fundamental statistics
Market CapNT$71.51b
Earnings (TTM)-NT$131.95m
Revenue (TTM)NT$74.87m

955.1x

P/S Ratio

-541.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4743 income statement (TTM)
RevenueNT$74.87m
Cost of RevenueNT$29.70m
Gross ProfitNT$45.17m
Other ExpensesNT$177.12m
Earnings-NT$131.95m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin60.33%
Net Profit Margin-176.25%
Debt/Equity Ratio0%

How did 4743 perform over the long term?

See historical performance and comparison

Valuation

Is Oneness Biotech undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


5.04x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4743's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4743's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 4743 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 4743 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4743's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4743 is overvalued based on its PB Ratio (5x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is Oneness Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oneness Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Oneness Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4743 is currently unprofitable.

Growing Profit Margin: 4743 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4743 is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.

Accelerating Growth: Unable to compare 4743's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4743 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 4743 has a negative Return on Equity (-0.98%), as it is currently unprofitable.


Financial Health

How is Oneness Biotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 4743's short term assets (NT$7.9B) exceed its short term liabilities (NT$176.9M).

Long Term Liabilities: 4743's short term assets (NT$7.9B) exceed its long term liabilities (NT$1.5B).


Debt to Equity History and Analysis

Debt Level: 4743 is debt free.

Reducing Debt: 4743 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4743 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4743 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 7.1% each year


Dividend

What is Oneness Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4743's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4743's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4743's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4743's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 4743 is not paying a notable dividend for the TW market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 4743 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.9yrs

Average board tenure


CEO

Chih-Hui Cheng

0.42

Tenure

Ms. Chih-Hui Cheng serves as General Manager and Supervisor of Corporate Governance at Oneness Biotech Co., Ltd. since December 30, 2021. She served as Deputy General Manager of Finance Department at Onene...


Board Members

Experienced Board: 4743's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Oneness Biotech Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Oneness Biotech Co., Ltd.
  • Ticker: 4743
  • Exchange: TPEX
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$71.507b
  • Shares outstanding: 386.52m
  • Website: https://www.onenessbio.com.tw

Number of Employees


Location

  • Oneness Biotech Co., Ltd.
  • No.236, Xinyi Road
  • 11th Floor
  • Taipei
  • 106
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.